In the Liraglutide Effects in Atrial Fibrillation (LEAF) Study, researchers at the University of Miami Miller School of Medicine, led by Jeffrey Goldberger, M.D., cardiac electrophysiologist and professor of cardiovascular medicine at the Miller School, found that adding the GLP1 receptor agonist liraglutide to a structured riskfactor modification program significantly improved freedom from AFib or atrial flutter one year after catheter ablation in overweight and obese patients
A medical weight loss visit at Ascend includes a physician-led history and exam, lab-based eligibility and contraindication screening, a documented medical record connected to your other care, and follow-up every 4 to 6 weeks through titration
Change in Color While a very slight yellow tint can be normal for some formulations, any significant change in colorsuch as turning dark yellow, brown, or pinkindicates that the medication has oxidized or reacted to light and heat
KK: Writing original draft, Writing review & editing
